The Pharma Letter M&A roundup - September 2022

6 October 2022

The big spenders stayed on holiday during September in pharmaceutical M&A markets—with the exception of Novo Nordisk (NOV: N).

Denmark's diabetes powerhouse expanded into the sickle cell disease and rare blood disorders with the $1.1 billion acquisition of Forma Therapeutics.

Swiss pharma giant Roche (ROG: SIX) was the only other of the industry's biggest players to announce a deal, in the shape of its $250 million buy of privately-held Seattle, USA-based drug developer Good Therapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK